SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending following the strategic sale of its Brazil operations for over $1 billion, a move largely seen as strengthening its balance sheet and focusing on North American growth with the recent first gold pour at its Greenstone Mine. Community discussion highlights analyst upgrades and high expectations for the company to achieve major gold producer status, despite some past frustration over share price performance.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following fresh analyst upgrades with significant price targets and a strategic U.S. manufacturing partnership for its high-performance silicon anode batteries. The community is keenly focused on the company's pivotal role in the burgeoning drone and defense industries, where its superior battery technology is seen as a necessity for extended mission capabilities.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF (VIXY) is trending as traders position for heightened market volatility, fueled by escalating geopolitical tensions and renewed threats of global tariffs. The community is actively discussing hedging strategies against perceived market complacency and the potential for significant downturns.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang Holdings is drawing attention as institutional accumulation and accelerating commercialization efforts across China, Thailand, and the Middle East highlight its advanced position in the burgeoning low-altitude economy, leading to community discussions about its significant undervaluation relative to global peers.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with strong community focus on the upcoming 4/20 event, as supporters champion its identity as the "culture coin" for the cannabis ecosystem, touting its long-term growth potential and current outperformance against traditional cannabis stocks.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed following a robust earnings report and anticipation of new Navenibart data at upcoming healthcare conferences. This combination drives investor optimism about pipeline potential and fuels heated debates around high short interest and management's approach to shareholder value.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar (GSAT) is trending amidst escalating speculation of a potential buyout from major tech players like SpaceX or Amazon, leveraging its uniquely valuable n53 spectrum and deepening Apple partnership. The community is eagerly anticipating key FCC decisions regarding spectrum use and the deployment of Globalstar's C-3 constellation, seen as critical catalysts, while highlighting its foundational role in direct-to-device connectivity and emerging IoT solutions.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is seeing heated discussion following its preliminary benchmark announcement for the Gemini-II AI chip, which proponents highlight for its edge AI efficiency and defense potential, while a significant portion of the community alleges misleading claims and market manipulation by the company and its promoters.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is highly volatile amid speculation of escalating geopolitical tensions in the Middle East and conflicting late-winter weather forecasts, prompting a community debate on whether a potential "polar vortex" or "LNG AI" demand can overcome sustained high production and the leveraged fund's inherent decay.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending after reporting robust Q3 earnings, fueled by its immunology portfolio and raised guidance, despite some market volatility; community discussion is highly focused on the company's strong intent to acquire an obesity asset, with Viking Therapeutics frequently cited as a key target to bolster future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -150.00% and -9.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevras executive officers and whether investor...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling...

Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an...

Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 91,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat Ratings...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 3,991,736 shares, a drop of 32.5...

Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - Here's What Happened

Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - What's Next...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$8.93
Prev Close	$9.09
Open	$8.93
Dividend Yield	0.00%
50-Day Moving Average	$8.70
Beta	0.89
Avg. Volume	1.04M
PE Ratio	14.41

52-Week High	$13.16
52-Week Low	$6.19
Market Capitalization	$511.74M
EPS (Annual)	-$2.28
Price to Book	3.84
Revenue Per Employee	$400,203.39

ZVRA
Zevra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVRA News

ZVRAZevra Therapeutics Inc